Is there a standard induction regimen for patients with AML?

Farhad Ravandi; Jorge Cortes; Hagop Kantarjian

doi:10.1016/S1470-2045(13)70183-9

Is there a standard induction regimen for patients with AML?

Farhad Ravandi, Jorge Cortes, Hagop Kantarjian

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	565-566
Number of pages	2
Journal	The Lancet Oncology
Volume	14
Issue number	7
DOIs	https://doi.org/10.1016/S1470-2045(13)70183-9
State	Published - Jun 2013
Externally published	Yes

ASJC Scopus subject areas

Oncology

Access to Document

10.1016/S1470-2045(13)70183-9

Cite this

@article{5bd08d5bd32643a2a2f98fe20ea601b6,

title = "Is there a standard induction regimen for patients with AML?",

author = "Farhad Ravandi and Jorge Cortes and Hagop Kantarjian",

note = "Funding Information: JC has been a consultant for Teva and has received research support from ChemGenex Pharmaceuticals. FR has received honoraria from, and been an advisory board member for, Teva. HK has received research grants from Novartis, Bristol-Myers Squibb, Pfizer, ARIAD, and ChemGenex. ",

year = "2013",

month = jun,

doi = "10.1016/S1470-2045(13)70183-9",

language = "English (US)",

volume = "14",

pages = "565--566",

journal = "The Lancet Oncology",

issn = "1470-2045",